ClinicalTrials.gg
CompletedNCT05105035Updated Feb 16, 2024

Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients

A Phase 2 interventional study of Ceftazidime or meropenem and ARV-1801 in Melioidosis, sponsored by Arrevus Inc.. Completed at 5 sites in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-16.

Sponsored by Arrevus Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study investigates the effect of 14 days of twice daily doses of ARV-1801 or placebo in combination with meropenem or ceftazidime in patients hospitalized with melioidosis.

Read the detailed description

ARV-1801 is an oral dosage form and loading dose regimen of sodium fusidate. Sodium fusidate is a member of the fusidane class of antibiotics. Recent evidence demonstrates meaningful activity against multiple biothreat agents, including the intracellular pathogen B. pseudomallei, which causes melioidosis. Once melioidosis is suspected clinically, treatment typically involves intravenous antibiotics such as ceftazidime or meropenem during an initial "intensive" phase (typically 2 weeks) and oral antibiotics such as co trimoxazole during a more chronic "eradication" phase (typically 12 weeks). Nevertheless, mortality can still exceed 40% in some regions, with most deaths occurring early during the eradication phase of therapy.

The purpose of this study is to evaluate the effects of ARV-1801 administered for 14 days in conjunction with the current standard of care (meropenem or ceftazidime) against placebo in conjunction with the current standard of care. Day 1 dosing will include two doses of 1500mg of ARV-1801 or placebo administered 12 hours apart. Days 2-14 will include 600 mg doses of ARV-1801 or placebo administered every 12 hours.

02

Conditions studied

  • Melioidosis

Keywords

  • meropenem
  • ceftazidime
  • B. pseudomallei
03

In context

Lead sponsor

Arrevus Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must provide written obtained prior to any study-specific procedure being performed.
  2. Patient must be at least 18 years of age or older at time of consent.
  3. Patient must be hospitalized with suspected community-acquired melioidosis, meeting at least one of the criteria below:

    • History of frequent contact with soil or surface water in an endemic area
    • Presence of a known underlying risk factor such as diabetes, renal insufficiency, renal stones or thalassemia
    • Special organ involvement such as splenic or hepatic abscess
    • An illness compatible with melioidosis, including the presence of sepsis, acute pneumonia, acute pyelonephritis, septic arthritis, parotid disease or skin or soft tissue infection
  4. Patient must require intravenous antibiotics i.e., either ceftazidime or meropenem for treatment of suspected melioidosis.
  5. Patient must agree to stay in hospital for duration of ARV-1801 therapy, i.e., 14 days.
  6. Females of must use an acceptable method of (surgically sterile, intrauterine device, vasectomized partner, oral contraceptive plus barrier contraceptive, hormone delivery system plus barrier contraceptive or condom in combination with contraceptive cream, jelly or foam) for the duration of the study drug administration phase and for 30 days thereafter.

Exclusion criteria

Exclusion Criteria:

  1. Patient is unable to tolerate oral therapy, either directly or via a nasogastric tube.
  2. Patient has a known infection with an identified organism other than B. pseudomallei.
  3. Patient is pregnant or lactating.
  4. Patient has a known to sodium fusidate, ceftazidime or meropenem.
  5. Patient has been treated with IV antibiotics active against B. pseudomallei (including ceftazidime and meropenem) for longer than 48 hours prior to randomization.
  6. Patient requires concomitant treatment with the following:

    • OATP1B1 and OATP1B3 substrates, in particular statins (e.g., HMG-CoA reductase inhibitors)
    • Medications metabolized by CYP2C8, such as glitazones (e.g., repaglinide)
    • inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital, and nafcillin)
  7. Patient has had prior treatment with a CYP3A4 inducer, such as dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital, or nafcillin, within 7 days prior to enrollment.
  8. Patient requires treatment with digoxin or warfarin unless a monitoring plan is in place to assess digoxin levels and/or as is relevant.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
125 participants (actual)

Study arms

  • Active comparator
    Placebo

    Patients are administered either IV ceftazidime or IV meropenem per standard of care and placebo. Placebo will be administered every 12 hours for Days 1-14.

    Drug: Ceftazidime or meropenem · Drug: Placebo

  • Experimental
    ARV-1801 (ACG-701)

    Patients are administered either IV ceftazidime or IV meropenem per standard of care and active ARV-1801. Day 1 dosing will be two doses of 1500mg of ARV-1801 administered 12 hours apart. Days 2-14 dosing will be 600mg of ARV-1801 administered every 12 hours.

    Drug: Ceftazidime or meropenem · Drug: ARV-1801

Interventions

  • DrugCeftazidime or meropenem

    Patients will be prescribed ceftazidime or meropenem intravenously as per standard of care for at least 14 days while in the hospital

  • DrugARV-1801

    Patients will be prescribed ARV-1801 at 1500mg 12 hours apart on Day 1 and 600mg every 12 hours for Days 2-14.

  • DrugPlacebo

    Patients will be prescribed placebo every 12 hours for Days 1-14.

06

What researchers measure

Primary outcomes

  1. All-cause in-hospital mortality through Day 14 in the modified intent-to-treat population (mITT)

    Time frame: Measured at Day 14

Secondary outcomes

  1. All-cause in-hospital mortality in mITT population

    Time frame: Measured at study completion, on average 28 days (assessed up to 60 days)

  2. All-cause in-hospital mortality through Day 14 in the ITT population

    Time frame: Measured at study completion, on average 28 days (assessed up to 60 days)

  3. All-cause in-hospital mortality in the ITT population

    Time frame: Measured at study completion, on average 28 days (assessed up to 60 days)

  4. Clearance of positive baseline B. pseudomallei blood cultures at Day 1, 3 and 7

    Time frame: Measured at Days 1, 3 and 7

  5. Number of days in the ICU in the mITT population

    Time frame: Measured at study completion, on average 28 days (assessed up to 60 days)

  6. Number of days on ventilator in the mITT population

    Time frame: Measured at study completion, on average 28 days (assessed up to 60 days)

  7. Length of hospital stay in the mITT population

    Time frame: Measured at study completion, on average 28 days (assessed up to 60 days)

  8. Melioidosis seriousness score in mITT population

    Time frame: Measured at Day 28

  9. Number of patients experiencing adverse events

    Time frame: Measured at study completion, on average 28 days (assessed up to 60 days)

07

Study locations

5 sites
  • Maharat Nakhonratchasima Hospital
    Nai Muang, Thailand
  • Srinagarind Hospital, Khon Kaen University
    Nai Muang, Thailand
  • Sunpasitthiprasong Hospital
    Nai Muang, Thailand
  • Surin Hospital
    Nai Muang, Thailand
  • Udon Thani Hospital
    Udon Thani, 41000, Thailand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Oct 2023, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2021
First posted
Nov 3, 2021
StartActual
Jun 14, 2022
Primary completionActual
Oct 10, 2023
CompletionActual
Oct 10, 2023
Last update
Feb 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05105035
Lead sponsor
Arrevus Inc.
Collaborators
Arnasi Group
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Jun 14, 2022
Primary completion
Oct 10, 2023
Completion
Oct 10, 2023
Last update
Feb 16, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion